vitality life science retatrutide Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation found. Adam Substack Series 3 of 6:

As the field evolves, SeekPeptides will continue providing the latest evidence-based guidance on optimal protocols

It is a triple receptor agonist that targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously

What we supply Explore our main supply categories, then contact us for availability and product documentation

Check your insurance plan or TrumpRX for current pricing

The current study Study author Yuya Koide and his colleagues wanted to explore how individuals with type 2 diabetes respond to GLP-1RAs therapy (Koide et al., 2025)

Phase 2 trial data showed a mean body weight reduction of approximately 24% at the 12 mg weekly maintenance dose over 48 weeks